

ABBREVIATED CURRICULUM VITAE
11-20-06

NAME: Sheldon Harrison Preskorn, M.D.

CITIZENSHIP: United States of America

MEDICAL SCHOOL: University of Kansas, Kansas City, Kansas (M.D., 1974)

WEBSITE: www.preskorn.com

POSTGRADUATE:

Pathology Residency,
University of Kansas Medical Center (UKMC) Kansas City, Kansas, 1973-75
Rotating Internship, Internal Medicine/Psychiatry
UKMC, Kansas City, Kansas, 1975-76
Psychiatry Residency,
Washington University School of Medicine, St. Louis, Missouri, 1976-78

ACADEMIC APPOINTMENTS:

Professor and Chairman, Department of Psychiatry and Behavioral Sciences,
University of Kansas School of Medicine (UKSM), Wichita, Kansas, 1999-Present
Professor and Vice Chairman, Department of Psychiatry,
UKSM, Wichita, Kansas, 1985-1999
Professor of Psychiatry and Pharmacology,
Washington University School of Medicine, St. Louis, Missouri, 1984-85
Associate Professor of Psychiatry and Pharmacology Toxicology and Therapeutics,
UKSM, Kansas City, Kansas, 1981-1984
Assistant Professor of Psychiatry and Pharmacology Toxicology and Therapeutics,
UKSM, Kansas City, Kansas, 1978-1981
Assistant Instructor in Psychiatry,
Washington University School of Medicine, St. Louis, Missouri, 1976-1978

DIRECTORSHIP POSITIONS:

President and CEO, Clinical Research Institute, 2003-Present
Wichita, Kansas
President and Medical Director, Psychiatric Research Institute, 1987-2003
Via Christi Regional Medical Center, Wichita, Kansas
Director, Outpatient Clinic Department of Psychiatry,
UKSM, Wichita, Kansas, 1991-1999
Chief, Psychiatry Service,
Wichita Veterans Administration Medical Center, Wichita, Kansas, 1985-1991

LICENSURE:

Permanent Kansas Medical License # 4-16344
Permanent Missouri Medical License # 00101337

CONSULTANTSHIP:

Menninger Foundation, Topeka, Kansas, 1992-98.

AWARDS:

Foxington Who's Who Directory of Executives and Professionals, 2000
National Registry of Who's Who, Life Member, 2000
The Best Doctors in America, 4th Edition, 1998
American Psychiatric Association, Nancy C.A. Roeske, M.D.,
Certificate of Excellence in Medical Student Education, 1998
National Alliance for the Mentally Ill, Exemplary Psychiatrist Award, 1993
The Mental Health Association in Kansas, 1989
Alliance for Mentally Ill in Sedgwick County, 1988
Research Scientist Development Award (NIMH), 1980-1985
American Academy of Clinical Psychiatry, Clinical Research Award, 1984
University of Kansas College of Health Sciences Research Award, 1983
American Academy of Clinical Psychiatry Annual Research Award, 1982
A.E. Bennett Neuropsychiatric Research Foundation Award, 1978
Roche Laboratory Award for Neuroscience, 1978
Mead-Johnson Award for Overall Excellence in Research, 1978
Walter C. Menninger Neuropsychiatry Award, 1978
Outstanding Young Men of America, 1977 and 1982
KUMC Psychiatric House Staff Research Award, 1976
KUMC Pathology House Staff Research Award, 1975
Chester M. Goodwin Award for Neurological Research, 1971
Who's Who in American Colleges and Universities, 1969

FELLOWSHIPS:

Maurice Falk Fellowship, 1975-1978
University of Kansas Research Fellowship, 1971
Wichita State University (WSU) Research Assistantship, 1970
WSU Honors Fellowship, 1969-1970

CERTIFICATION:

Psychiatry plus Geriatric qualifications, American Board of Psychiatry and Neurology, 1997
Diplomat, American Board of Psychiatry and Neurology, 1981
Diplomat, National Board of Medical Examiners, 1975

EDITORIAL BOARDS:

Associate Editor, Journal of Clinical Psychiatry, 2001
Associate Editor, Journal of Clinical Psychopharmacology, 2000
Contributing Editor, Journal of Psychiatric Practice, 2000-Present
Contributing Editor, Journal of Practical Psychiatry and Behavioral Health, 1995-1999
American Hospital Formulary Service Drug Information, 1998
Associate Editor, Journal of Clinical Psychiatry, 1978-1988
Associate Editor, Current Psychiatry, 2003-Present

MAJOR RESEARCH INTEREST:

Psychopharmacology, affective and anxiety disorders, neuroscience.

REVIEW COMMITTEES:

Canadian Psychiatric Research Foundation
Panel Member, Center for Scientific Review, NIMH Special Emphasis Panel, 1999-Present
Panel Member, Center for Scientific Review, NIH Study Sect.-Genetic Sciences, 1999
Member, International Advisory Board for the Guidelines in Depression, 1998-2000
Member, Via Christi Regional Medical Center Institutional Review Board, 1989-
Moderator-Faculty, American Psychiatric Association Physician Awareness Program, 1987-89
Reviewer (Member), Wesley Foundation Scientific Advisory Panel, 1987-1989
Reviewer (ad hoc), VA Merit Rev. Mental Health and Behavioral Science Comm., 1985
Reviewer (ad hoc), Nat'l Inst. Neurological and Communicative Disorders and Stroke (NINCDS) study section on Spinal Cord Trauma Centers, 1983 and 1987

Reviewer (ad hoc) National Science Foundation Neuropharmacology Section, 1983-1987
Reviewer (ad hoc), NIMH Psychopharmacological, Biological, and Physical Treatments Research Review Committee (TDA2), 1986
Member, FDA Psychopharmacologic Drugs Advisory Committee, 1982-1986
Reviewer (ad hoc), NIMH Mental Health Behavioral Science Research Review, 1984

SOCIETIES:

International Society for Affective Disorders, 2001-2002
American Psychopathological Association, Fellow, 1989
American Psychiatric Association, Member, 1979; Fellow, 1987, Distinguished Fellow, 2003
Society of Neuroscience, Member 1978; Local Chapter Secretary/Treasurer 1980; President 1981-1982
American Society of Clinical Pharmacology and Therapeutics, Member, 1979
Society of Biological Psychiatry, Member, 1978
Alpha Omega Alpha, Member, 1973
American Medical Association, Member, 1971
Phi Kappa Phi, Member, 1970
Omicron Delta Kappa, President, 1969
WSU Honors Society, Member, 1969

GRANTS:

Continuous funding since 1978. Supplemental report available

ORGANIZATIONAL OFFICES:

Member, Sedgwick County Task Force on Suicide Prevention, 2001-Present
Scientific Advisor, Mental Health Association of South Central Kansas, 2001-2006
NIMH Outreach and Education, 2000-Present
Sedgwick County Alliance for Mentally Ill, 1996-Present
Advisory Committee, Kansas Alliance for the Mentally Ill, 1993-Present
Member, University of Kansas School of Medicine Research Committee, 1992-1994
Member, Board of Directors, Project Awareness for Major Mental Illness, 1990-Present
Founding President, Project Awareness for Major Mental Illness, 1990-Present
Member, Scientific Program Committee for American Society of Clinical Pharmacology and Therapeutics, 1983-1985
Chairman, KUMC Faculty and Student Affairs Committee, 1983-1984
Member, Governor's Advisory Commission on Mental Health and Retardation Services and Community Mental Health Programs, State of Kansas, 1979-1984
Member, American Psychiatric Association Program Committee (National), 1978-1982
Chairman, Subcommittee on New Research, 1980-1982
Member, American Psychiatric Association Council - Research and Development, 1976 -1978
Member, American Psychiatric Association Task Force Tardive Dyskinesia, 1976-1979
Member, Continuing Education Committee for Kansas Psychiatric Society, 1980-1982
Member, KUMC Human Studies Research Committee, 1979-1984
Member, KUMC Peer Utilization Review Committee, 1978-1980
Representative, KUMC House staff Association, 1976
Representative, Association of American Medical Colleges, 1971-1973
Treasurer, KUMC Chapter (student) of the Kansas Medical Society, 1970-1971
President/Administrative/Executive Coordinator, WSU Student Union Activities Board, 1969-1970
Educational/Cultural Coordinator, WSU Student Union Activities Board, 1968-1969
Chairman, Wichita Film Society, 1967-1968

VISITING PROFESSOR/LECTURER:

Presented at meetings and/or universities in the following cities on one or more occasions:

Foreign Countries

Brisbane, Australia
Melbourne, Australia
Sydney, Australia
Hobart, Australia
Vienna, Australia
Brussels, Belgium
Hamilton, Bermuda
Rio de Janeiro, Brazil
Edmonton, Canada
Halifax, Canada
Hamilton, Canada
London, Canada
Montreal, Canada
Toronto, Canada
Regina, Canada
Saskatchewan, Canada
Vancouver, Canada
Winnipeg, Canada
Beijing, China
Hong Kong, China
Shanghai, China
Copenhagen, Denmark
Odense, Denmark
Alexandria, Egypt
Cairo, Egypt
Oxford, England
London, England
Cannes, France
Nice, France
Paris, France
Berlin, Germany
Dresden, Germany
Frankfurt, Germany
Giessen, Germany
Hamburg, Germany
Hannover, Germany
Marburg, Germany
Muenster, Germany
Tuebingen, Germany
Athens, Greece
Rhodes, Greece
Budapest, Germany
Jerusalem, Israel
Cagliari, Italy
Florence, Italy
Palermo, Italy
Rome, Italy
Venice, Italy
Kyoto, Japan
Seoul, Korea
Mexico City, Mexico
Acapulco, Mexico
Monte Carlo, Monaco
Amsterdam, Netherlands
Auckland, New Zealand
Oslo, Norway
Trondheim, Norway
Tromso, Norway
Las Croabas, Puerto Rico
San Juan, Puerto Rico
Glasgow, Scotland
Capetown, South Africa
Tromso, Norway
Al-Khobar, Saudi Arabia
Dammam, Saudi Arabia
Jeddah, Saudi Arabia
Riyadh, Saudi Arabia
Johannesburg, South Africa
Badojoz, Spain
Barcelona, Spain
Madrid, Spain
Linkoping, Sweden
Lund, Sweden
Stockholm, Sweden
Basel, Switzerland
Berne, Switzerland
Geneva Switzerland
Lausanne, Switzerland
Zurich, Switzerland
Taipei, Taiwan
Anoyla, Turkey
Istanbul, Turkey
Dubai, United Arab Emirates

United States

Baylor University
Boston University
Bowman University
Case Western Reserve University
Chicago University
Cleveland Clinic
Columbia University
Cornell University
Creighton University
Duke University
East Carolina University
George Washington University
Georgetown University
Harvard University-Beth Israel Hospital
Harvard University-Massachusetts Mental Health Center
Harvard University-Massachusetts General Hospital
Harvard University-McLean Hospital
Henry Ford Hospital-Detroit
Howard University
John Hopkins University
Loma Linda University
Louisiana State University-Shreveport
Louisiana State University-New Orleans
Loyola University
Mayo Clinic
Medical College of Ohio
Medical College of South Carolina
Menninger Foundation
New York University
Northwestern University
Ohio State University
Oklahoma Department of Mental Health
Purdue University
Rush Presbyterian University
Southern Illinois University-Springfield
Southwestern Medical College-Dallas
St. Louis University
Stanford University
State University of New York-Albany
State University of New York-Buffalo
State University of New York-Stony Brook
Texas Tech University
Thomas Jefferson University
Tufts University
Tulane University
University of Alabama-Birmingham
University of Arizona
University of Arkansas
University of California-Davis
University of California-Irvine
University of California-Los Angeles
University of California-Sacramento
University of California-San Francisco
University of California-San Diego
University of Colorado
University of Connecticut-Institute of Living
University of Hawaii
University of Iowa
University of Kentucky
University of Louisville
University of Maine
University of Miami
University of Michigan
University of Minnesota
University of Mississippi
University of Missouri-Columbia
University of Missouri-Kansas City
University of Nebraska
University of Nevada-Las Vegas
University of Nevada-Reno
University of New Hampshire
University of New Jersey Dental
University of New Mexico
University of North Dakota
University of Ohio
University of Oklahoma-Oklahoma City
University of Oregon
University of Pennsylvania
University of Pittsburg
University of South Dakota
University of South Florida
University of South Carolina-Columbia
University of Southern Alabama
University of Southern California
University of Tennessee
University of Texas-Austin
University of Texas-Galveston
University of Utah
University of Washington-Seattle
University of Washington-Spokane
University of Vermont
University of Virginia
University of Wisconsin
University of Wisconsin-Madison
University of Wisconsin-Milwaukee
University of Wisconsin Medical College
Vanderbilt University
Washington University
Wayne State University
Wichita State University

SUMMARIZED PUBLICATIONS:

Total publications over 400. Principal topics have been basic and clinical psychopharmacology, psychiatric drug development, affective and anxiety disorders, and neuroscience.

ITEMIZED PUBLICATIONS: (abbreviated CV only contains publications since 1999)

JOURNAL ARTICLES:

Journal Articles:

- (1) Preskorn SH. Antidepressant options in primary care. *Clinical Cornerstone* 1999; 1(4):31-54.
Ref ID: 2996
- (2) Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants: Cost implications and relevance to clinical practice. *Clin Pharmacokinet* 1999; 37(2):147-165.
Ref ID: 2991
- (3) Catterson ML, Martin RL, Preskorn SH. Psychopharmacological drug-drug interactions in the elderly. *Clinical Geriatrics* 1999; 7(9):46-54.
Ref ID: 3201
- (4) Harvey AT, Rudolph RL, Preskorn SH. Evidence of the dual mechanisms of action of venlafaxine. *Arch Gen Psychiatry* 2000; 57(5):503-509.
Ref ID: 7050
- (5) Findling RL, Preskorn SH, Marcus RN, Magnus RD, D'Amico F, Marathe P et al. Nefazodone pharmacokinetics in depressed children and adolescents. *J Am Acad Child Adolesc Psychiatry* 2000; 39(8):1008-1016.
Ref ID: 3458
- (6) Shad M, Marsh C, Preskorn SH. The economic consequences of a drug-drug interaction. *Journal of Clinical Psychopharmacology* 2001; 21(1):119-120.
Ref ID: 4137
- (7) Harvey AT, Preskorn SH. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. *Journal of Clinical Psychopharmacology* 2001; 21(2):161-166.
Ref ID: 4936
- (8) Fava M, Dunner DL, Greist JH, Preskorn SH, Trivedi MH, Zajecka J et al. Efficacy and safety in mirtazapine in depressed patients after SSRI treatment failure: An open-label trial. *J Clin Psychiatry* 2001; 62(6):413-420.
Ref ID: 5005
- (9) Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild A, Snavely D et al. Demonstration of the efficacy and safety of a novel substance P(NK₁) receptor antagonist (SPA) in major depression. *Neuropsychopharmacology* 2004; 29(2):385-392.
Ref ID: 5008
- (10) Werder SF, Preskorn SH. Managing polypharmacy Walking the fine line. *Current Psychiatry* 2003; 2(2):24-36.
Ref ID: 7290
- (11) Preskorn SH, Flockhart DA. 2004 Guide to psychiatric drug interactions. *Primary Psychiatry* 2004; 11(2):39-60.
Ref ID: 6645
- (12) Preskorn SH. How drug-drug interactions can impact managed care. *Am J Manag Care* 2004; 10(6):S186-S198.
Ref ID: 6695
- (13) Preskorn SH. Why patients may not respond to usual recommended dosages. *Curr Psychiatry* 2004; 3(8):38-43.
Ref ID: 6822

- (14) Harvey AT, Flockhart DA, Gorski JC, Greenblatt DJ, Burke M, Werder SF et al. Intramuscular haloperidol or lorazepam and QT intervals in schizophrenia. *J Clin Pharmacol* 2004; 44:1173-1184.
Ref ID: 6482
- (15) Reyes JF, Preskorn SH, Khan AY, Kumar D, Cullen EI, Perdomo CA et al. Concurrent administration of donepezil HCl and risperidone in patients with schizophrenia: Assessment of pharmacokinetic changes and safety following multiple oral doses. *BJCP* 2004; 58(1):50-57.
Ref ID: 5572
- (16) Khan AY, Preskorn SH, D'Empaire I. Something in the air. *Curr Psychiatry* 2004; 3(12):79-88.
Ref ID: 6824
- (17) Preskorn SH, Silkey B, Shah R, Neff M, Jones TL, Choi J et al. Complexity of medication use in the veterans affairs healthcare system: Part I: Outpatient use in relation to age and number of prescribers. *J Psych Prac* 2005; 11(1):5-15.
Ref ID: 6840
- (18) Silkey B, Preskorn SH, Shah R. Complexity of medication use in the Veterans Affairs Healthcare System: Part II. Antidepressant use among younger and older outpatients. *J Psych Prac* 2005; 11(1):16-26.
Ref ID: 6835
- (19) Ramadan MI, Khan AY, Preskorn SH. D2-Blockade and possible ziprasidone-induced galactorrhea. *J Clin Psychopharm* 2005; 20(2):113-114.
Ref ID: 6550
- (20) Preskorn SH. Pharmacokinetics and therapeutics of intramuscular ziprasidone. *Clin Pharmacokinet* 2005; 44(11).
Ref ID: 8658
- (21) Khan AY, Preskorn SH, Wimalasena K. Stereoisomerism in psychopharmacology: an overview. *Curr Psychiatry*. In press.
Ref ID: 6790
- (22) Khan AY, Preskorn SH, Baker B. Effect of study criteria on recruitment and generalizability of the results. *J Clin Psychopharmacol* 2005 Jun;25(3):271-5.
Ref ID: 8577
- (23) Ahsan YK, Carrithers J, Preskorn SH, Wisniewski SR, Lear R, Rush AJ et al. Clinical and demographic factors associated with DSM-IV melancholic depression. *Ann Clin Psychiatr*. 2006.
Ref ID: 6792
- (24) Preskorn SH. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. *Clin Pharmacokinet* 2006;44(11):1117-33.
Ref ID: 8658
- (25) Preskorn SH, Flockhart DA. 2006 Guide to psychiatric drug interactions. *Primary Psychiatry* 2006 13(4) 51-80..
Ref ID: 8896
- (26) Khan AY, Preskorn SH, Wimalasena K. Single enantiomer drugs" should they be developed. *Essent Psychopharm* 2006;7(1):15-23.
Ref ID: 9049
- (27) Preskorn SH. Pharmacogenomics informatics and individual drug therapy in psychiatry: past present and future. *J Psychopharm* 2006;20(suppl 4):85-94.
Ref ID: 9057
- (28) Preskorn SH, Werder SF. Detrimental antidepressant drug-drug interactions: Are they clinically relevant? *Neuropsychopharmacology* 2006; 31:1605-1612.
Ref ID: 8605

- (29) Preskorn SH. Counterpoint. *Neuropsychopharmacology* 2006; 31(8):1614-1615.
Ref ID: 9125
- (30) Ramadan MI, Werder SF, Preskorn SH. Protect against drug-drug interactions with anxiolytics. *Curr Psychiatr* 2006; 5(5):16-28.
Ref ID: 6838
- (31) Khan AY, Preskorn SH, Wimalasena K. Single enantiomer drugs" should they be developed. *Essent Psychopharm* 2006; 7(1):15-23.
Ref ID: 9049
- (32) Preskorn SH. Pharmacogenomics informatics and individual drug therapy in psychiatry: past present and future. *J Psychopharm* 2006; 20(suppl 4):85-94.
Ref ID: 9057
- (33) Preskorn SH, Greenblatt DJ, Flockhart DA, Luo Y, Perloff ES, Harmatz JS et al. Comparison of duloxetine, escitalopram and sertraline effects on cytochrome P450 (CYP) 2D6 function in healthy volunteers. *J Clin Pharmacol* 2007.
Ref ID: 8690

Columns:

- (1) Preskorn SH. The slippery slide. *J Prac Psych and Behav Hlth* 1999; 5(1):50-55.
Ref ID: 3056
- (2) Preskorn SH. Finding the signal through the noise: The use of surrogate markers. *J Prac Psych and Behav Hlth* 1999; 5(2):104-109.
Ref ID: 2800
- (3) Preskorn SH. A tale of two patients. *J Prac Psych and Behav Hlth* 1999; 5(3):160-164.
Ref ID: 2853
- (4) Preskorn SH. Defining "is". *J Prac Psych and Behav Hlth* 1999; 5(4):224-228.
Ref ID: 3057
- (5) Preskorn SH. De-spinning in vitro data. *J Prac Psych and Behav Hlth* 1999; 5(5):283-287.
Ref ID: 3160
- (6) Preskorn SH. Two in one: The venlafaxine story. *J Prac Psych and Behav Hlth* 1999; 5(6):346-350.
Ref ID: 3159
- (7) Preskorn SH. Bupropion: What mechanism of action? *J Prac Psych and Behav Hlth* 2000; 6(1):39-44.
Ref ID: 3216
- (8) Preskorn SH. Imipramine, mirtazapine, and nefazodone: Multiple targets. *J Prac Psych and Behav Hlth* 2000; 6(2):97-102.
Ref ID: 3215
- (9) Preskorn SH. The adverse effect of the selective serotonin reuptake inhibitors: Relationship to in vitro pharmacology. *J Psych Prac* 2000; 6(3):218-223.
Ref ID: 4174
- (10) Preskorn SH. The relative adverse effect profile of non-SSRI antidepressants: Relationship to in vitro pharmacology. *Journal of Psychiatric Practice* 2000; 6(4):218-223.
Ref ID: 4372
- (11) Preskorn SH. The human genome project and modern drug development in psychiatry. *Journal of Psychiatric Practice* 2000; 6(5):272-276.
Ref ID: 4608

- (12) Preskorn SH. The stages of drug development and the human genome project: Drug discovery. *Journal of Psychiatric Practice* 2000; 6(6):341-344.
Ref ID: 4619
- (13) Preskorn SH, Silkey B. Multiple medications, multiple considerations. *Journal of Psychiatric Practice* 2001; 7(1):48-52.
Ref ID: 4807
- (14) Preskorn SH. The human genome project and drug discovery in psychiatry: Identifying novel targets. *Journal of Psychiatric Practice* 2001; 7(2):133-140.
Ref ID: 4928
- (15) Preskorn SH. Antipsychotic drug development in the pre-human-genome era: A full circle. *Journal of Psychiatric Practice* 2001; 7(3):209-213.
Ref ID: 5010
- (16) Preskorn SH. Drug discovery in psychiatry: Drilling down on the target of interest. *Journal of Psychiatric Practice* 2001; 7(4):267-272.
Ref ID: 5011
- (17) Preskorn SH. Drug development in psychiatry and the human genome project: The explosion in knowledge and potential targets. *Journal of Psychiatric Practice* 2001; 7(5):336-340.
Ref ID: 5138
- (18) Preskorn SH. Drug development in psychiatry and genomics: From E.coli to man. *Journal of Psychiatric Practice* 2001; 7(6):415-419.
Ref ID: 5524
- (19) Preskorn SH. Drug approvals and withdrawals over the last 60 years. *Journal of Psychiatric Practice* 2002; 7(8):41-50.
Ref ID: 5558
- (20) Preskorn SH, Silkey B, Jones TL. Physician perceptions of drug-drug interactions and how to avoid them. *Journal of Psychiatric Practice* 2002; 8(2):112-115.
Ref ID: 5600
- (21) Preskorn SH, Baker B. The overlap of DSM-IV syndromes: Potential implications for the practice of polypharmacology, psychiatric drug development and the human genome project. *Journal of Psychiatric Practice* 2002; 8(3):170-177.
Ref ID: 5589
- (22) Preskorn SH. Fatal drug-drug interactions as a differential consideration in apparent suicides. *Journal of Psychiatric Practice* 2002; 8(4):233-238.
Ref ID: 5631
- (23) Preskorn SH. Clinical pharmacology case conference: A suicide attempt? *Journal of Psychiatric Practice* 2002; 8(5):306-310.
Ref ID: 5746
- (24) Preskorn SH. Polypharmacy in a patient with refractory major depression: Part I: The case. *Journal of Psychiatric Practice* 2002; 8(6):370-376.
Ref ID: 5699
- (25) Preskorn SH. Polypharmacy in a case of refractory major depression: Part II: Implications for clinical management. *J Psych Prac* 2003; 9(1):71-78.
Ref ID: 5636
- (26) Preskorn SH. Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part I). *Journal of Psychiatric Practice* 2003; 9(2):150-158.
Ref ID: 5814

- (27) Reproducibility of the in vivo effect of the selective serotonin reuptake inhibitors on the in vivo function of cytochrome P450 2D6: An update (part II). 2003.
Ref ID: 7352
- (28) Preskorn SH. Relating clinical trials to Psychiatric Practice: Part I: The case of a 13-year old on Aripiprazole and fluoxetine. *J Psych Prac* 2003; 9(4):307-313.
Ref ID: 6448
- (29) Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions. *J Psych Prac* 3 A.D.; 10(3):177-181.
Ref ID: 6634
- (30) Preskorn SH. Classification of neuropsychiatric medications by principal mechanism of action: A meaningful way to anticipate pharmacodynamically mediated drug interactions (Part II). *J Psych Prac* 2004;10(3):177-81.
Ref ID: 8652
- (31) Preskorn SH. Relating clinical trials to psychiatric practice: Part II: the gap between the usual patient in registration trials and in practice. *J Psych Prac* 2003; 9(6):455-461.
Ref ID: 6525
- (32) Preskorn SH. Reboxetine: A selective norepinephrine reuptake pump inhibitor. *J Psych Prac* 2004; 10(1):57-63.
Ref ID: 6551
- (33) Preskorn SH. Milnacipran: A dual norepinephrine and serotonin reuptake pump inhibitor. *J Psych Prac* 2004; 10(2):119-126.
Ref ID: 6598
- (34) Preskorn SH. Exceeding the recommended dose range: Conceptualizing and monitoring high-dose drug therapy. *J Psych Prac* 2004; 10(4):249-254.
Ref ID: 6801
- (35) Preskorn SH. Tianeptine: A facilitator of the reuptake of serotonin and norepinephrine as an antidepressant. *J Psych Prac* 2004; 10(5):323-330.
Ref ID: 6791
- (36) Preskorn SH. Duloxetine. *J Psych Prac* 2004; 10(6):375-385.
Ref ID: 6823
- (37) Preskorn SH. Multiple medication Use in patients seen in the Veterans Affairs Healthcare System: So what? *J Psych Prac* 2005; 11(1):46-50.
Ref ID: 6837
- (38) Preskorn SH. Drug-Drug interactions: Proof of relevance. *J Psych Prac* 2005; 11(2):116-122.
Ref ID: 8568
- (39) Preskorn SH. Drug-Drug Interactions: Proof of relevance (Part II): Cause of tolerability problems or noncompliance. *J Psych Prac* 2005;11(6):397-401.
Ref ID: 8770
- (40) Preskorn SH. The difference between the formal and the functional dose: The case of the patient of thioridazine and fluvoxamine. *J Psych Prac* 2005; 11(3):192-196.
Ref ID: 8576
- (41) Preskorn SH. Clinical application of the concept of relative potency: An example involving chlorpromazine and haloperidol. *J Psych Prac* 2005; 11(4):258-261.
Ref ID: 8655

- (42) Khan AY, Preskorn SH. Examining concentration-dependent toxicity of clozapine: Role of therapeutic drug monitoring. *J Psych Prac* 2005; 11(5):1-13.
Ref ID: 8654
- (43) Preskorn SH. Comments on the role of therapeutic drug monitoring for clozapine. *J Psych Prac* 2005; 11(5):340-343.
Ref ID: 8689
- (44) Preskorn SH. Psychopharmacology and psychotherapy: what's the connection. *J Psych Prac* 2006; 12(1):41-45.
Ref ID: 8822
- (45) Preskorn SH. Patient with bipolar disorder and familial QT prolongation: What to do? *J Psych Prac* 2006;12(2):109-12.
Ref ID: 8894
- (46) Preskorn SH. Why the transdermal delivery of selegiline obviates the need for a dietary restriction on tyramine. *J Psych Prac* 2006;12(3):168-72.
Ref ID: 9004
- (47) Preskorn SH. Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: part I. *J Psych Prac* 2006;12(4):244-9.
Ref ID: 9104
- (48) Preskorn SH, Borges-Gonzalez S, Flockhart DA. Clinically relevant pharmacology of neuropsychiatric drugs approved over the last three years: Part II. *J Psych Prac* 2006; 12(5):312-316.
Ref ID: 9140
- (49) Preskorn SH. Drugs are an acquired source of biological variance among patients. *J Psych Prac* 2006; 12(6):391-396.
Ref ID: 9257

Book Chapters:

- (1) Preskorn SH, Harvey AT. Cytochrome P450 enzymes and psychopharmacology. In: Watson SJ, editor. Fourth Generation of Progress . 1998.
Ref ID: 2251
- (2) Shad MU, Preskorn SH. Antidepressants. In: Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M, editors. Metabolic Drug Interactions. Philadelphia: Lippincott, Williams & Wilkins, 2000: 563-577.
Ref ID: 3405
- (3) Preskorn SH. Methodological issues in psychopharmacogenetics. In: Lerer B, editor. Pharmacogenetics of Psychotropic Drugs. NY: Cambridge University, 2002: 57.
Ref ID: 7041
- (4) Preskorn SH. Mood disorders method of. In: Rakel RE, Bope ET, editors. Conn's Current Therapy. Philadelphia: Saunders (Elsevier Science), 2003: 1196-1204.
Ref ID: 7292
- (5) Khan AY, Preskorn SH. Pharmacokinetic principles and drug interactions. Handbook of medical psychiatry. 2003: 945-944.
Ref ID: 6597
- (6) Preskorn SH, Catterson ML. General principles of pharmacokinetics. In: Preskorn SH, Feighner JP, Stanga CY, Ross R, editors. Antidepressants: Past, present and future. Heidelberg: Springer-Verlag, 2004: 35-86.
Ref ID: 6589
- (7) Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants. In: Preskorn SH, Feighner JP, Stanga CY, Ross R, editors. Antidepressants: Past, present and future. Heidelberg: Springer-Verlag, 2004: 87-114.
Ref ID: 6590
- (8) Preskorn SH, Ross R. Overview of currently available antidepressants. In: Preskorn SH, Feighner JP, Stanga CY, Ross R, editors. Antidepressants: Past, present and future. Heidelberg: Springer-Verlag, 2004: 171-183.
Ref ID: 6591

- (9) Preskorn SH, Ross R, Stanga CY. Selective serotonin reuptake inhibitors. In: Preskorn SH, Feighner JP, Stanga CY, Ross R, editors. Antidepressants: Past, present and future. Heidelberg: Springer-Verlag, 2004: 241-262.
Ref ID: 6592
- (10) Preskorn SH, Ross R. Other antidepressants. In: Preskorn SH, Feighner JP, Stanga CY, Ross R, editors. Antidepressants: Past, present and future. Heidelberg: Springer-Verlag, 2004: 263-324.
Ref ID: 6593
- (11) Preskorn SH. Role of pharmacogenetics/pharmacogenomics in the development of new antidepressants. In: Preskorn SH, Feighner JP, Stanga CY, Ross R, editors. Antidepressants: Past, present and future. Heidelberg: Springer-Verlag, 2004: 583-607.
Ref ID: 6594

Books

- (1) Preskorn SH. Outpatient Management of Depression. 2nd ed. Caddo: Professional Communications, Inc., 1999.
Ref ID: 8702
- (2) Janicak P, Davis JM, Preskorn SH, Ayd FJ Jr. Principles and practice of psychopharmacotherapy. Philadelphia: Lippincott Williams and Wilkins, 2001:
Ref ID: 4733
- (3) Preskorn SH, Feighner JP, Stanga CY, Ross R. Handbook of Experimental Pharmacology Antidepressants: Past, Present, and Future. Heidelberg: Springer-Verlag, 2004.
Ref ID: 8701
- (4) Preskorn SH, Flockhart DA. Psychotropic drug Interactions Guide. New York: MBL Communications, 2004.
Ref ID: 6635
- (5) Janicak PG, Davis JM, Preskorn SH, Ayd FJ, Jr., Marder SR, Pavuluri MN. Principles and practice of psychopharmacology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2006
Ref ID: 8906

Abstracts:

- (1) Shad MU, Preskorn SH, Miceli J, Wilner K. Use of population pharmacokinetic modeling to characterize intramuscular pharmacokinetics for ziprasidone in schizophrenic patients. Clin Pharmacol Ther 65, 171. 1999.
Ref ID: 2790
- (2) Shad MU, Carmichael CA, Preskorn SH, Horst WD. The nature and extent of polypharmacy in patients on antidepressants as a function of treatment setting. Clin Pharmacol Ther 65, 183. 1999.
Ref ID: 2791
- (3) Preskorn SH. Pharmacogenetic research in clinical psychopharmacology: Design and methodological challenges. Int'l J Neuropsychopharmacology 3[suppl 1], S5. 2000.
Ref ID: 4190
- (4) Silkey B, Preskorn SH, Golbeck A, Horst WD. Addressing health risks/costs associated with multiple medication use in a veterans integrated service network. 2000. Drug Information Association 2nd Annual Workshop on "Pharmaceutical Outcomes Research".
Ref ID: 3913
- (5) Silkey B, Preskorn SH, Golbeck A. Interindividual variability in steady-state plasma levels of bupropion and its major metabolites. 2000. 40th Annual NCDEU.
Ref ID: 4050
- (6) Reyes JF, Preskorn SH, Khan AY, Kumar D, Cullen E. Pharmacokinetics (PK) of donepezil and risperidone in males with schizophrenia (poster). Clinical Pharmacology and Therapeutics 69, 44. 2001.
Ref ID: 4888

- (7) Harvey AT, Preskorn SH. The influence of extended-release venlafaxine on QT intervals of normal volunteers. Unknown . 2001.
Ref ID: 5534
- (8) Khan AY, Friesen S, Klick-Davis A, Preskorn SH. How inclusion and exclusion criteria affect the ability to randomize patients in a clinical trial for schizophrenia/schizo-affective disorder. 2001. NCDEU 41st Annual meeting, May 28-31, 2001, Phoenix, AZ.
Ref ID: 5536
- (9) Preskorn SH, Baker B. The clinical pharmacology of antidepressants: Relevance to the optimum management of the depressed patient. AANP . 2001.
Ref ID: 5537
- (10) Harvey AT, Preskorn SH. The influence of intramuscular (IM) haloperidol (HAL) or lorazepam (LOR) on QT intervals of volunteers with schizophrenia. *Clinical Pharmacology and Therapeutics* 71[2], P53. 2002.
Ref ID: 5114
- (11) Preskorn SH, Silkey B, Shah R, Neff M. Multiple medication use and cytochrome P-450 based drug interaction patterns in patients on antidepressants in a regional veterans affairs health care network. *Clinical Pharmacology & Therapeutics* 71[2], 59. 2002.
Ref ID: 5653
- (12) Wesnes KA, Preskorn SH, Friesen S, Edgar C, Mikkelsen BO. NS 2330 enhances cognitive function in normal volunteers and volunteers with possible Alzheimer's disease (AD). 2002.
Ref ID: 5597
- (13) Preskorn SH, Shah R, Silkey B, Neff M, Golbeck A, Choi J. The potential for clinically significant drug-drug interactions in patients receiving CYP 2D6 model substrate/drugs and fluoxetine/paroxetine or sertraline. *Clin Pharm Ther* 75[2], 71. 2004.
Ref ID: 6483
- (14) Preskorn SH, Baker B, Klick-Davis A *et al.* The effect of duloxetine, escitalopram, and sertraline on CYP 2D6 function. *Clin Pharm Ther* 2006;79(2):52.
Ref ID: 8893

Letters to the Editor:

- (1) Shad MU. Drug-drug interaction in reverse: Possible loss of phenytoin efficacy as a result of fluoxetine discontinuation. *J Clin Pharmacol* 1999; 19(5):471-472.
Ref ID: 3155
- (2) Shad MU, Preskorn SH, Izgur Z. Failure to consider drug-drug interactions as a likely cause of behavioral deterioration in a patient with bipolar disorder. *J Clin Psychiatry* 2000; 20(3):390-392.
Ref ID: 4113
- (3) Khan AY, Shad MU, Preskorn SH. Lack of sertraline efficacy probably due to an interaction with carbamazepine. *J Clin Psychiatry* 2000; 61(7):526-527.
Ref ID: 3844
- (4) Preskorn SH, Greenblatt DJ, Harvey AT. Lack of effect of sertraline on the pharmacokinetics of alprazolam. *Journal of Clinical Psychopharmacology* 2000; 20(5):585-586.
Ref ID: 4694
- (5) Khan AY, Preskorn SH. Increase in plasma levels of clozapine and norclozapine after administration of nefazodone. *J Clin Psychiatry* 2001; 62(5):375-376.
Ref ID: 5123

Special Presentations:

Visiting Professor for Annual Psychopharmacology Day:

1997-University of Toronto in Toronto, Ontario, Canada
1998-University of Alberta in Edmonton, Alberta, Canada
1999-University of Hamilton in Hamilton, Ontario, Canada

Sept. 14, 2002 – German Neuroscience Academy in Versailles, France. “Drug development in psychiatry and the human genome project: Implications for clinical practice.”

Oct. 2, 2002 – Keynote address at Annual Psychopharmacology Update Program for the University of Oklahoma at Tulsa. “Drug-drug interactions: Their mechanisms, their clinical presentation, and their clinical relevance.”

Oct. 6, 2002 – Keynote address at Annual Psychopharmacology Update Program for the University of Mississippi in Jacksonville, MS. “The rational basis for the combined use of more than one psychiatric medication.”